[Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
We estimated antitumor activity of TUT-7 following p.o. administration using animal tumor models and human tumor xenografts. In mouse L 1210 leukemia system, antitumor activity of TUT-7 administered orally was as good as that by i.v. administration. Treatment involving schedules of every 4-days or daily administration was much more effective than single treatment. Therapiotic indices of this compound administered both p.o. or i.v. routes, were better than that of adriamycin administered i.v.. TUT-7 showed antitumor activities against various mouse tumors (L 1210 leukemia, P 388 leukemia, colon 38 adenocarcinoma, B 16 melanoma), LX-1 human tumor xenografts, and Yoshida sarcoma in rat. Base on above results, we concluded that oral administration is one of the useful route of TUT-7 administration.
Sugimoto
Y
Y
Biological Research Laboratory, Taiho Phamaceutical Co., Ltd., Japanese Foundation for Cancer Research.
Matsuo
K
K
Takeda
S
S
Yamada
Y
Y
Tsukagoshi
S
S
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy; D017290:Menogaril; D051379:Mice; D009621:Nogalamycin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D051381:Rats; D012517:Sarcoma, Yoshida / Q000188:drug therapy
D000970:Antineoplastic Agents; D004317:Doxorubicin; D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin